Treatment of Prostate and Bladder cancers      

FOI REFERENCE: 24562  FOI DATE: 28^th November 2024      

PROSTATE CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Name of medicine		Number patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)		45
1.2 Apalutamide (Erleada)		44
1.3 Cabazitaxel (Jevtana or generic cabazitaxel)		8
1.4 Darolutamide (Nubeqa)		27
1.5 Enzalutamide (Xtandi)		181

Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Name of medicine		Number patients treated
2.1 Docetaxel for prostate cancer		0
2.2 Olaparib (Lynparza) for prostate cancer		1
2.3 Talazoparib (Talzenna) for prostate cancer		0

Q3. How many patients were treated with the following combinations in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Name of medicine		Number patients treated
3.1 Darolutamide (Nubeqa) + Docetaxel + ADT		28
3.2 Olaparib (Lynparza) + Abiraterone		16

Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuprorelin, triptorelin, degarelix, flutamide

Q4. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?   

Name of medicine		Number patients treated
4.1 Abiraterone		18
4.2 Enzalutamide		41

BLADDER CANCER

Q5. How many patients were treated for bladder cancer (ICD-10 code = C67*) with the following products in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?  

Name of medicine		Number patients treated
5.1 Atezolizumab (Tecentriq)		5
5.2 Avelumab (Bavencio)		10
5.3 Erdafitinib (Balversa)		0
5.4 Nivolumab (Opdivo)		0
5.5 Pembrolizumab (Keytruda)		0

Q6. Of the patients treated with nivolumab (Opdivo) for bladder cancer, how many were treated in the following settings in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

Combination, monotherapy, adjuvant		Number patients treated
6.1 Nivolumab in combination with cisplatin and gemcitabine		0
6.2 Nivolumab monotherapy as adjuvant treatment		0
6.3 Nivolumab monotherapy in total		0

ATEZOLIZUMAB (TECENTRIQ)

Q7. How many patients were treated with atezolizumab (Tecentriq) for the following cancer types in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?  

Cancer type		Number patients treated
7.1 Lung Cancer		22
7.2 Breast Cancer		1
7.3 Hepatocellular Carcinoma		0

Q8. How many of the patients treated with atezolizumab were treated in the following settings in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?  

Combination, monotherapy, adjuvant		Number patients treated
8.1 Atezolizumab in combination with carboplatin and etoposide		5
8.2 Atezolizumab as adjuvant treatment		0
8.3 Atezolizumab in combination with bevacizumab, carboplatin and paclitaxel		1